레미케이드 바이오시밀러 시장 규모, 점유율, 동향, 성장 분석 보고서(2026-2034년)

The global Remicade biosimilar market size is expected to reach USD 42.32 Billion in 2034 from USD 5.56 Billion in 2025, growing at a CAGR of 25.29 during 2026-2034.This market is witnessing strong growth driven by increasing demand for cost-effective biologic therapies used in the treatment of autoimmune and inflammatory diseases. Remicade biosimilars provide therapeutic alternatives for conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. Rising healthcare costs and growing pressure to improve treatment accessibility are encouraging healthcare systems to adopt biosimilar products. Regulatory support for biosimilar approvals is further contributing to market expansion.

Healthcare providers and payers are increasingly embracing biosimilars as they offer comparable efficacy and safety at lower costs than reference biologics. Growing awareness among physicians and patients regarding the benefits of biosimilars is supporting wider adoption. Expanding reimbursement coverage and favorable healthcare policies are also driving market growth. In addition, increasing prevalence of chronic inflammatory disorders continues to generate sustained demand for biologic therapies.

Future prospects remain highly promising as healthcare systems focus on cost containment and broader patient access to advanced treatments. Ongoing biosimilar development programs and regulatory harmonization efforts are expected to strengthen market competitiveness. Emerging economies are likely to become important growth regions due to expanding healthcare access and affordability initiatives. As biologic therapy utilization continues increasing, the Remicade biosimilar market is projected to experience sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• 100mg/10ml
• 500mg/50ml

By Disease Indication

• Ulcerative Colitis
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Crohn-(TM)s Disease
• Psoriatic Arthritis
• Plaque Psoriasis

By Application

• Blood Disorders
• Oncology Diseases

COMPANIES PROFILED

• Novartis AG, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck & Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-Iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd., Shanghai Biomabs Pharmaceuticals Co. Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL REMICADE BIOSIMILAR MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. 100mg/10ml Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. 500mg/50ml Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL REMICADE BIOSIMILAR MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Ulcerative Colitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Rheumatoid Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Ankylosing Spondylitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Crohn-(TM)s Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Psoriatic Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Plaque Psoriasis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL REMICADE BIOSIMILAR MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Blood Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oncology Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL REMICADE BIOSIMILAR MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Disease Indication
  • 7.2.3 By Application
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Disease Indication
  • 7.3.3 By Application
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Disease Indication
  • 7.4.3 By Application
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Disease Indication
  • 7.5.3 By Application
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Disease Indication
  • 7.6.3 By Application
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL REMICADE BIOSIMILAR INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis AG
  • 9.2.2 Amgen Inc
  • 9.2.3 Viatris Inc
  • 9.2.4 Teva Pharmaceutical Industries Ltd
  • 9.2.5 Biogen Inc
  • 9.2.6 Merck & Co. Inc
  • 9.2.7 LG Chem Ltd
  • 9.2.8 Nippon Kayaku Co. Ltd
  • 9.2.9 Celltrion Inc
  • 9.2.10 Nichi-Iko Pharmaceutical Co. Ltd
  • 9.2.11 Biocon Limited
  • 9.2.12 Alvotech S.A
  • 9.2.13 MabPharm Ltd
  • 9.2.14 Genor Biopharma Co. Ltd
  • 9.2.15 Shanghai Biomabs Pharmaceuticals Co. Ltd